RCS - Intnl. Biotechnology - Latest Factsheet and Blog

International Biotechnology Trust

25/06/2024 13:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240625:nRSY8189Ta&default-theme=true

RNS Number : 8189T  Intl. Biotechnology Trust PLC  25 June 2024

INTERNATIONAL BIOTECHNOLOGY TRUST PLC ("IBT")

 

Latest Factsheet and Blog

 

 

IBT's factsheet for the month ended 31 May 2024 is now available directly via
its web page. Please click here
(https://www.schroders.com/en-gb/uk/individual/funds-and-strategies/investment-trusts/international-biotechnology-trust/)
, then 'latest factsheet'.

 

Following a challenging three years, the biotechnology sector has put in a
much more encouraging performance in recent months. With valuations still
attractive, balance sheets looking strong and an improving funding
environment, we take a look at the multiple reasons to be positive about the
outlook for biotechnology investors in the years ahead.

 

The blog can be read here:

 

www.ibtplc.com/emerging-from-the-biotech-bear-market-in-great-shape/
(https://www.schroders.com/en-gb/uk/individual/content/emerging-from-the-biotech-bear-market-in-great-shape/)

 

To sign up for IBT updates by email, please click here
(https://www.schroders.com/en-gb/uk/individual/never-miss-an-update/) .

 

 

ENDS

 

 

Enquiries:

 

 Schroder Investment Management Limited

 Kirsty Preston (PR)                                                       020 7658 6000

 Kerry Higgins (Company Secretary)                                         020 7658 6000

 Kaso Legg Communications (Financial PR)

 Charles Gorman                                                            IBT@kl-communications.com (mailto:IBT@kl-communications.com)

 Henry Taylor

 Effie Aye Maung Hider

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRALELFLZQLFBBE